Akero Therapeutics Inc AKRO
News
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
Madrigal's stock surges as FDA approves first drug for liver disease MASH
Akero Therapeutics shares plunge on liver disease treatment's mixed results